Pediatric Cytomegalovirus Infection Workup: Laboratory Studies, Imaging Studies, Other Tests (original) (raw)

Laboratory Studies

The laboratory studies discussed below may be indicated in patients with cytomegalovirus (CMV) infection.

Viral culture is the most important diagnostic study in the evaluation of suspected CMV disease. CMV may be cultured from virtually any body fluid or organ system. Blood, urine, saliva, cervicovaginal secretions, cerebrospinal fluid (CSF), bronchoalveolar lavage fluid, and tissues from biopsy specimens are all appropriate specimens for culture. The specimen is inoculated onto human cells (usually human foreskin fibroblasts), and the cell culture is monitored for development of the characteristic CMV-associated cytopathic effect.

Shell vial assay is a centrifugation enhancement monoclonal-antibody culture technique that is an adaptation of tissue culture. It provides results more rapidly, which can be advantageous because although culture is highly sensitive, clinical isolates of CMV may grow slowly, requiring as long as 6 weeks of incubation in the virology laboratory. In shell vial assay, the clinical specimen is centrifuged onto a cell monolayer (in effect, concentrating the specimen). Then, following incubation in tissue culture, cells are stained with a monoclonal antibody to a CMV-specific antigen, usually an immediate early gene product. A positive shell vial culture is presumptive evidence of active CMV infection, and the test is a useful adjunct to traditional viral culture. [45]

Polymerase chain reaction (PCR) [46] and CMV antigenemia studies have emerged in recent years as the studies of choice in monitoring the status of CMV replication and establishing the diagnosis of CMV disease in immunocompromised patients. Of these, PCR is most commonly used owing to its convenience and its ability to be processed in automated fashion. The magnitude of the viral load in blood as determined by quantitative PCR in immunocompromised patients is a valuable parameter in making the decision to initiate preemptive therapy, toward the goal of preventing serious CMV end-organ disease. [47, 48] PCR can also be used to make the diagnosis of congenital CMV infection, using blood, urine and saliva as appropriate fluids for study, and quantitative PCR in infected newborns may prove to be useful in monitoring response to antiviral therapy.

Exercise caution when obtaining and interpreting CMV diagnostic studies in young infants. By definition, the diagnosis of congenital CMV infection requires identification of the virus in a culture specimen acquired before age 3 weeks because perinatally acquired infections may also begin to manifest at this time. Hence, a positive viral culture obtained in infants older than 3 weeks may simply represent perinatal or breast milk acquisition and may not be interpreted as evidence of congenital CMV infection.

Although theoretically helpful, CMV immunoglobulin M (IgM) assays are unfortunately too nonspecific to reliably diagnose congenital CMV infection. False-positive results are common; therefore, making the diagnosis of congenital infection outside of the immediate perinatal period is very difficult.

Universal screening for congenital CMV infection may be a reasonable future goal and could enable establishment of appropriate anticipatory neurodevelopmental and serial audiological screening programs. A study demonstrated that, unfortunately, the use of the newborn blood spot to screen for congenital CMV infection is unreliable, because of suboptimal sensitivity. [49] Therefore, alternative approaches to universal CMV screening need to be developed.

Outside of the neonatal period, the major caution regarding CMV diagnosis is to use diagnostic studies appropriately to differentiate between CMV infection (the presence of CMV in blood or body fluids without proof of end-organ damage) and CMV disease.

Infants and children infected with CMV may shed the virus for years, making a positive urine viral culture difficult to interpret.

Immunocompromised patients often have reactivation of latent CMV with subsequent viral shedding, even in the absence of overt CMV disease. Thus, the identification of CMV by culture in urine or saliva may reflect such chronic shedding of virus and is difficult to interpret in the evaluation of patients with end-organ disease, such as pneumonitis or hepatitis.

Lung biopsy or bronchoalveolar lavage may be necessary to confirm the diagnosis of CMV pneumonitis.

Hepatitis may require liver biopsy for confirmation of the diagnosis, and CMV hepatitis and chronic rejection may be a difficult differential diagnosis in liver transplant recipients, even with a biopsy.

eMedicine Logo

Imaging Studies

Congenital cytomegalovirus (CMV) infection

The most important study in the diagnostic evaluation of the congenitally infected infant with CMV is head CT scanning (see the image below).

Cranial CT scan of infant born with symptomatic co

Cranial CT scan of infant born with symptomatic congenital cytomegalovirus infection. Neurological involvement is evident, manifest as ventriculomegaly and periventricular calcifications.

A CT scan of the head is required for infants with microcephaly or when congenital CMV infection is suspected because abnormalities in this study, particularly the presence of calcifications, have a strong positive predictive value and can aid in identifying children who need ongoing neurodevelopmental evaluation and therapy.

Evidence suggests that head ultrasonography may be of equal value to CT scanning in evaluation of potential intracranial pathology in the setting of congenital CMV infection.

Infants with congenital CMV infection may also require abdominal imaging studies (eg, ultrasonography, CT scanning) for documentation and monitoring of organomegaly.

Other CMV syndromes

Depending on the patient population, radiographic studies are seldom of value in evaluation of CMV disease.

Exceptions include the rare patient with severe mononucleosis caused by primary CMV infection who may require abdominal ultrasonography for monitoring of splenomegaly or the immunocompromised patient who requires chest radiography studies for the possibility of CMV pneumonitis.

eMedicine Logo

Other Tests

Other tests are indicated, based on the organ systems involved and manifestations of disease syndromes.

eMedicine Logo

Procedures

Procedures depend on the age of the patient and manifestations of disease syndromes. For infants, procedures may include lumbar puncture or liver biopsy.

For immunocompromised transplant recipients, bronchoalveolar lavage, tissue or organ biopsy, and lumbar puncture may all be required to evaluate for extent of cytomegalovirus (CMV)-associated disease. For some patients with AIDS who have retinitis, placement of ganciclovir-impregnated intravitreal implants may be an important ancillary procedure.

eMedicine Logo

Histologic Findings

The classic tissue histological finding in cytomegalic disease is the inclusion cell; however, viral culture, serology, antigenemia, and nucleic acid detection systems (eg, PCR) generally have much better sensitivity for the diagnosis of cytomegalovirus (CMV)–associated diseases. Histopathology, therefore, typically is not needed to establish the diagnosis of CMV infection in most settings.

eMedicine Logo

  1. Schleiss MR. Persistent and recurring viral infections: the human herpesviruses. Curr Probl Pediatr Adolesc Health Care. 2009 Jan. 39(1):7-23. [QxMD MEDLINE Link].
  2. Soderberg-Naucler C. Does cytomegalovirus play a causative role in the development of various inflammatory diseases and cancer?. J Intern Med. 2006 Mar. 259(3):219-46. [QxMD MEDLINE Link].
  3. Goodpasture EQ, Talbot FB. Concerning the nature of "protozoan-like" cells in certain lesions of infancy. Am J Dis Child. 1921. 21:415.
  4. Weller TH, Hanshaw JB. Virologic and clinical observations on cytomegalic inclusion disease. N Engl J Med. 1962 Jun 14. 266:1233-44. [QxMD MEDLINE Link].
  5. Weller TH. The cytomegaloviruses: ubiquitous agents with protean clinical manifestations. I. N Engl J Med. 1971 Jul 22. 285(4):203-14. [QxMD MEDLINE Link].
  6. Schleiss MR, McVoy MA. Overview of congenitally and perinatally acquired cytomegalovirus infections: recent advances in antiviral therapy. Expert Rev Anti Infect Ther. 2004 Jun. 2(3):389-403. [QxMD MEDLINE Link].
  7. Sung H, Schleiss MR. Update on the current status of cytomegalovirus vaccines. Expert Rev Vaccines. 2010 Nov. 9(11):1303-14. [QxMD MEDLINE Link].
  8. Schleiss MR. Congenital cytomegalovirus infection: molecular mechanisms mediating viral pathogenesis. Infect Disord Drug Targets. 2011 Oct. 11(5):449-65. [QxMD MEDLINE Link].
  9. Kimberlin DW, Lin CY, Sanchez PJ, et al. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J Pediatr. 2003 Jul. 143(1):16-25. [QxMD MEDLINE Link].
  10. Wang D, Shenk T. Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. Proc Natl Acad Sci U S A. 2005 Dec 13. 102(50):18153-8. [QxMD MEDLINE Link].
  11. Ryckman BJ, Jarvis MA, Drummond DD, Nelson JA, Johnson DC. Human cytomegalovirus entry into epithelial and endothelial cells depends on genes UL128 to UL150 and occurs by endocytosis and low-pH fusion. J Virol. 2006 Jan. 80(2):710-22. [QxMD MEDLINE Link].
  12. Sylwester AW, Mitchell BL, Edgar JB, Taormina C, Pelte C, Ruchti F. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med. 2005 Sep 5. 202(5):673-85. [QxMD MEDLINE Link].
  13. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995 Oct 19. 333(16):1038-44. [QxMD MEDLINE Link].
  14. Miller-Kittrell M, Sparer TE. Feeling manipulated: cytomegalovirus immune manipulation. Virol J. 2009 Jan 9. 6:4. [QxMD MEDLINE Link]. [Full Text].
  15. Schleiss MR. Can we build it better? Using BAC genetics to engineer more effective cytomegalovirus vaccines. J Clin Invest. 2010 Dec. 120(12):4192-7. [QxMD MEDLINE Link].
  16. Ho M. Epidemiology of cytomegalovirus infections. Rev Infect Dis. 1990 Sep-Oct. 12 Suppl 7:S701-10. [QxMD MEDLINE Link].
  17. Pesch MH, Schleiss MR. Emerging concepts in congenital cytomegalovirus. Pediatrics. 2022 Aug 1. 150 (2):[QxMD MEDLINE Link].
  18. Kenneson A, Cannon MJ. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol. 2007 Jul-Aug. 17(4):253-76. [QxMD MEDLINE Link].
  19. Dar L, Pati SK, Patro AR, et al. Congenital cytomegalovirus infection in a highly seropositive semi-urban population in India. Pediatr Infect Dis J. 2008 Sep. 27(9):841-3. [QxMD MEDLINE Link].
  20. Boppana SB, Ross SA, Novak Z, Shimamura M, Tolan RW Jr, Palmer AL. Dried blood spot real-time polymerase chain reaction assays to screen newborns for congenital cytomegalovirus infection. JAMA. 2010 Apr 14. 303(14):1375-82. [QxMD MEDLINE Link].
  21. Kabani N, Ross SA. Congenital cytomegalovirus infection. J Infect Dis. 2020 Mar 5. 221 (Suppl 1):S9-S14. [QxMD MEDLINE Link]. [Full Text].
  22. Leruez-Ville M, Foulon I, Pass R, Ville Y. Cytomegalovirus infection during pregnancy: state of the science. Am J Obstet Gynecol. 2020 Sep. 223 (3):330-49. [QxMD MEDLINE Link].
  23. Dworsky M, Yow M, Stagno S, Pass RF, Alford C. Cytomegalovirus infection of breast milk and transmission in infancy. Pediatrics. 1983 Sep. 72(3):295-9. [QxMD MEDLINE Link].
  24. Hamele M, Flanagan R, Loomis CA, Stevens T, Fairchok MP. Severe morbidity and mortality with breast milk associated cytomegalovirus infection. Pediatr Infect Dis J. 2010 Jan. 29(1):84-6. [QxMD MEDLINE Link].
  25. Bate SL, Dollard SC, Cannon MJ. Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988-2004. Clin Infect Dis. 2010 Jun 1. 50(11):1439-47. [QxMD MEDLINE Link].
  26. Cannon MJ, Schmid DS, Hyde TB. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol. 2010 Jul. 20(4):202-13. [QxMD MEDLINE Link].
  27. Adler SP, Starr SE, Plotkin SA, Hempfling SH, Buis J, Manning ML. Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. J Infect Dis. 1995 Jan. 171(1):26-32. [QxMD MEDLINE Link].
  28. Fowler KB, Pass RF. Risk factors for congenital cytomegalovirus infection in the offspring of young women: exposure to young children and recent onset of sexual activity. Pediatrics. 2006 Aug. 118(2):e286-92. [QxMD MEDLINE Link].
  29. [Guideline] Kaplan JE, Masur H, Holmes KK. Guidelines for preventing opportunistic infections among HIV-infected persons--2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. MMWR Recomm Rep. 2002 Jun 14. 51:1-52. [QxMD MEDLINE Link].
  30. Colugnati FA, Staras SA, Dollard SC, Cannon MJ. Incidence of cytomegalovirus infection among the general population and pregnant women in the United States. BMC Infect Dis. 2007 Jul 2. 7:71. [QxMD MEDLINE Link]. [Full Text].
  31. Gunkel J, de Vries LS, Jongmans M, Koopman-Esseboom C, van Haastert IC, Eijsermans MCJ, et al. Outcome of Preterm Infants With Postnatal Cytomegalovirus Infection. Pediatrics. 2018 Feb. 141 (2):[QxMD MEDLINE Link].
  32. Boppana SB, Rivera LB, Fowler KB, Mach M, Britt WJ. Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity. N Engl J Med. 2001 May 3. 344(18):1366-71. [QxMD MEDLINE Link].
  33. Schleiss MR. Cytomegalovirus vaccines and methods of production (WO20009049138): the emerging recognition of the importance of virus neutralization at the epithelial/endothelial interface. Expert Opin Ther Pat. 2010 Apr. 20(4):597-602. [QxMD MEDLINE Link].
  34. Dollard SC, Grosse SD, Ross DS. New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev Med Virol. 2007 Sep-Oct. 17(5):355-63. [QxMD MEDLINE Link].
  35. Bale JF, Miner L, Petheram SJ. Congenital Cytomegalovirus Infection. Curr Treat Options Neurol. 2002 May. 4(3):225-230. [QxMD MEDLINE Link].
  36. Cheeran MC, Lokensgard JR, Schleiss MR. Neuropathogenesis of congenital cytomegalovirus infection: disease mechanisms and prospects for intervention. Clin Microbiol Rev. 2009 Jan. 22(1):99-126, Table of Contents. [QxMD MEDLINE Link].
  37. Williamson WD, Demmler GJ, Percy AK, Catlin FI. Progressive hearing loss in infants with asymptomatic congenital cytomegalovirus infection. Pediatrics. 1992 Dec. 90(6):862-6. [QxMD MEDLINE Link].
  38. Fowler KB, McCollister FP, Dahle AJ, Boppana S, Britt WJ, Pass RF. Progressive and fluctuating sensorineural hearing loss in children with asymptomatic congenital cytomegalovirus infection. J Pediatr. 1997 Apr. 130(4):624-30. [QxMD MEDLINE Link].
  39. Foulon I, Naessens A, Foulon W, Casteels A, Gordts F. A 10-year prospective study of sensorineural hearing loss in children with congenital cytomegalovirus infection. J Pediatr. 2008 Jul. 153(1):84-8. [QxMD MEDLINE Link].
  40. Torpy JM, Burke AE, Glass RM. JAMA patient page. Cytomegalovirus. JAMA. 2010 Apr 14. 303(14):1440. [QxMD MEDLINE Link].
  41. Cannon MJ, Davis KF. Washing our hands of the congenital cytomegalovirus disease epidemic. BMC Public Health. 2005. 5:70. [QxMD MEDLINE Link].
  42. Fowler KB, Dahle AJ, Boppana SB, Pass RF. Newborn hearing screening: will children with hearing loss caused by congenital cytomegalovirus infection be missed?. J Pediatr. 1999 Jul. 135(1):60-4. [QxMD MEDLINE Link].
  43. Horwitz CA, Henle W, Henle G, et al. Clinical and laboratory evaluation of cytomegalovirus-induced mononucleosis in previously healthy individuals. Report of 82 cases. Medicine (Baltimore). 1986 Mar. 65(2):124-34. [QxMD MEDLINE Link].
  44. Barton LL, Mets MB. Congenital lymphocytic choriomeningitis virus infection: decade of rediscovery. Clin Infect Dis. 2001 Aug 1. 33(3):370-4. [QxMD MEDLINE Link].
  45. Gleaves CA, Smith TF, Shuster EA, Pearson GR. Comparison of standard tube and shell vial cell culture techniques for the detection of cytomegalovirus in clinical specimens. J Clin Microbiol. 1985 Feb. 21(2):217-21. [QxMD MEDLINE Link]. [Full Text].
  46. Demmler GJ, Buffone GJ, Schimbor CM, May RA. Detection of cytomegalovirus in urine from newborns by using polymerase chain reaction DNA amplification. J Infect Dis. 1988 Dec. 158(6):1177-84. [QxMD MEDLINE Link].
  47. Ljungman P, Hakki M, Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Hematol Oncol Clin North Am. 2011 Feb. 25(1):151-69. [QxMD MEDLINE Link].
  48. Razonable RR. Cytomegalovirus infection after liver transplantation: current concepts and challenges. World J Gastroenterol. 2008 Aug 21. 14(31):4849-60. [QxMD MEDLINE Link].
  49. Boppana SB, Ross SA, Novak Z, Shimamura M, Tolan RW Jr, Palmer AL. Dried blood spot real-time polymerase chain reaction assays to screen newborns for congenital cytomegalovirus infection. JAMA. 2010 Apr 14. 303(14):1375-82. [QxMD MEDLINE Link].
  50. Pass RF, Zhang C, Evans A, et al. Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med. 2009 Mar 19. 360(12):1191-9. [QxMD MEDLINE Link]. [Full Text].
  51. Griffiths PD, Stanton A, McCarrell E, Smith C, Osman M, Harber M. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet. 2011 Apr 9. 377(9773):1256-63. [QxMD MEDLINE Link].
  52. Josephson CD, Caliendo AM, Easley KA, Knezevic A, Shenvi N, Hinkes MT, et al. Blood transfusion and breast milk transmission of cytomegalovirus in very low-birth-weight infants: a prospective cohort study. JAMA Pediatr. 2014 Nov. 168(11):1054-62. [QxMD MEDLINE Link].
  53. Kharfan-Dabaja MA, Boeckh M, Wilck MB, Langston AA, Chu AH, Wloch MK. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2012 Apr. 12(4):290-9. [QxMD MEDLINE Link].
  54. Tastad KJ, Schleiss MR, Lammert SM, Basta NE. Awareness of congenital cytomegalovirus and acceptance of maternal and newborn screening. PLoS One. 2019. 14 (8):e0221725. [QxMD MEDLINE Link]. [Full Text].
  55. Adler SP. Cytomegalovirus and child day care. Evidence for an increased infection rate among day-care workers. N Engl J Med. 1989 Nov 9. 321(19):1290-6. [QxMD MEDLINE Link].
  56. Schleiss M, Stanberry L. Herpesvirus infections of the neonatal CNS: Similarities and differences between HSV and CMV. Herpes. 1997. 4:74.
  57. Schleiss MR. Prospects for development and potential impact of a vaccine against congenital cytomegalovirus (CMV) infection. J Pediatr. 2007 Dec. 151(6):564-70. [QxMD MEDLINE Link].
  58. Tabata T, McDonagh S, Kawakatsu H, Pereira L. Cytotrophoblasts infected with a pathogenic human cytomegalovirus strain dysregulate cell-matrix and cell-cell adhesion molecules: a quantitative analysis. Placenta. 2007 May-Jun. 28(5-6):527-37. [QxMD MEDLINE Link].
  59. Zhang C, Buchanan H, Andrews W, Evans A, Pass RF. Detection of cytomegalovirus infection during a vaccine clinical trial in healthy young women: seroconversion and viral shedding. J Clin Virol. 2006 Mar. 35(3):338-42. [QxMD MEDLINE Link].

Author

Mark R Schleiss, MD Minnesota American Legion and Auxiliary Heart Research Foundation Chair of Pediatrics, Professor of Pediatrics, Division Director, Division of Infectious Diseases and Immunology, Department of Pediatrics, University of Minnesota Medical School

Mark R Schleiss, MD is a member of the following medical societies: American Pediatric Society, Infectious Diseases Society of America, Pediatric Infectious Diseases Society, Society for Pediatric Research

Disclosure: Nothing to disclose.

Pharmacy Editor

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Chief Editor

Russell W Steele, MD Clinical Professor, Tulane University School of Medicine; Staff Physician, Ochsner Clinic Foundation

Russell W Steele, MD is a member of the following medical societies: American Academy of Pediatrics, American Association of Immunologists, American Pediatric Society, American Society for Microbiology, Infectious Diseases Society of America, Louisiana State Medical Society, Pediatric Infectious Diseases Society, Society for Pediatric Research, Southern Medical Association

Disclosure: Nothing to disclose.

Acknowledgements

Leslie L Barton, MD Professor Emerita of Pediatrics, University of Arizona College of Medicine

Leslie L Barton, MD is a member of the following medical societies: American Academy of Pediatrics, Association of Pediatric Program Directors, Infectious Diseases Society of America, and Pediatric Infectious Diseases Society

Disclosure: Nothing to disclose.